IS7504A - Arýl keton pýrróló-tríazín efnasambönd gagnleg sem kínasatálmar - Google Patents
Arýl keton pýrróló-tríazín efnasambönd gagnleg sem kínasatálmarInfo
- Publication number
- IS7504A IS7504A IS7504A IS7504A IS7504A IS 7504 A IS7504 A IS 7504A IS 7504 A IS7504 A IS 7504A IS 7504 A IS7504 A IS 7504A IS 7504 A IS7504 A IS 7504A
- Authority
- IS
- Iceland
- Prior art keywords
- kinase inhibitors
- compounds useful
- triazine compounds
- aryl ketone
- pyrrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37490702P | 2002-04-23 | 2002-04-23 | |
PCT/US2003/012420 WO2003091229A1 (en) | 2002-04-23 | 2003-04-18 | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IS7504A true IS7504A (is) | 2004-10-14 |
Family
ID=29270567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7504A IS7504A (is) | 2002-04-23 | 2004-10-14 | Arýl keton pýrróló-tríazín efnasambönd gagnleg sem kínasatálmar |
Country Status (14)
Country | Link |
---|---|
US (1) | US7314876B2 (is) |
EP (1) | EP1503996B1 (is) |
JP (1) | JP2005529890A (is) |
AR (1) | AR039648A1 (is) |
AT (1) | ATE418546T1 (is) |
AU (1) | AU2003221753A1 (is) |
DE (1) | DE60325469D1 (is) |
ES (1) | ES2318122T3 (is) |
IS (1) | IS7504A (is) |
NO (1) | NO20044592L (is) |
PE (1) | PE20040411A1 (is) |
PL (1) | PL373371A1 (is) |
TW (1) | TW200306841A (is) |
WO (1) | WO2003091229A1 (is) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
DK1497019T3 (en) * | 2002-04-23 | 2015-08-03 | Bristol Myers Squibb Co | PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS |
EP1503996B1 (en) | 2002-04-23 | 2008-12-24 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6951859B2 (en) * | 2002-08-02 | 2005-10-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
KR20050100615A (ko) | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
CN1771234A (zh) | 2003-02-05 | 2006-05-10 | 布里斯托尔-迈尔斯斯奎布公司 | 吡咯并三嗪激酶抑制剂的制备方法 |
US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
MXPA06014495A (es) | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
US7534882B2 (en) | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US20070161617A1 (en) | 2005-12-15 | 2007-07-12 | Morgan Bradley P | Certain chemical entities, compositions and methods |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8063208B2 (en) * | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
BRPI0708644A2 (pt) | 2006-03-07 | 2011-06-07 | Bristol-Myers Squibb Company | compostos de pró-fármaco de anilina de pirrolotriazina úteis como inibidores de cinase |
AR074830A1 (es) | 2008-12-19 | 2011-02-16 | Cephalon Inc | Pirrolotriazinas como inhibidores de alk y jak2 |
WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
AU8381098A (en) | 1997-07-02 | 1999-01-25 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
EP1117653B1 (en) | 1998-10-01 | 2003-02-05 | AstraZeneca AB | Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
MXPA01011832A (es) * | 1999-05-21 | 2002-06-21 | Squibb Bristol Myers Co | Inhibidores de cinasas, de pirrolotriazina. |
US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
PT1140939E (pt) | 1999-11-10 | 2005-05-31 | Ortho Mcneil Pharm Inc | 2-aril-3-(heteroaril)- imidazo [1,2-alfa] pirimidinas substituidas, e formulacoes farmaceuticas e metodos relacionados |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
JP2004522713A (ja) | 2000-11-17 | 2004-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | p38キナーゼ関連疾患の処置方法およびキナーゼインヒビターとして有用なピロロトリアジン化合物 |
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
TW200300350A (en) | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
EP1503996B1 (en) | 2002-04-23 | 2008-12-24 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
TWI272271B (en) | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6951859B2 (en) | 2002-08-02 | 2005-10-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
TW200420565A (en) | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
-
2003
- 2003-04-18 EP EP03718493A patent/EP1503996B1/en not_active Expired - Lifetime
- 2003-04-18 AT AT03718493T patent/ATE418546T1/de not_active IP Right Cessation
- 2003-04-18 PL PL03373371A patent/PL373371A1/xx not_active Application Discontinuation
- 2003-04-18 JP JP2003587789A patent/JP2005529890A/ja not_active Withdrawn
- 2003-04-18 TW TW092109124A patent/TW200306841A/zh unknown
- 2003-04-18 AU AU2003221753A patent/AU2003221753A1/en not_active Abandoned
- 2003-04-18 ES ES03718493T patent/ES2318122T3/es not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012420 patent/WO2003091229A1/en active Application Filing
- 2003-04-18 DE DE60325469T patent/DE60325469D1/de not_active Expired - Lifetime
- 2003-04-22 US US10/420,445 patent/US7314876B2/en not_active Expired - Lifetime
- 2003-04-23 AR ARP030101400A patent/AR039648A1/es unknown
- 2003-04-23 PE PE2003000401A patent/PE20040411A1/es not_active Application Discontinuation
-
2004
- 2004-10-14 IS IS7504A patent/IS7504A/is unknown
- 2004-10-25 NO NO20044592A patent/NO20044592L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1503996A1 (en) | 2005-02-09 |
EP1503996B1 (en) | 2008-12-24 |
PE20040411A1 (es) | 2004-07-14 |
NO20044592L (no) | 2004-11-19 |
PL373371A1 (en) | 2005-08-22 |
ATE418546T1 (de) | 2009-01-15 |
JP2005529890A (ja) | 2005-10-06 |
AU2003221753A1 (en) | 2003-11-10 |
US7314876B2 (en) | 2008-01-01 |
TW200306841A (en) | 2003-12-01 |
DE60325469D1 (de) | 2009-02-05 |
ES2318122T3 (es) | 2009-05-01 |
US20030232831A1 (en) | 2003-12-18 |
WO2003091229A1 (en) | 2003-11-06 |
EP1503996A4 (en) | 2006-05-17 |
AR039648A1 (es) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7504A (is) | Arýl keton pýrróló-tríazín efnasambönd gagnleg sem kínasatálmar | |
IS8345A (is) | 6-útskipt anilínópúrín sem RTK-tálmar | |
IS7505A (is) | Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar | |
IS7884A (is) | Díasepínóindól afleiður sem kínasa hindrar | |
IL173381A0 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
DK1699797T3 (da) | Pyrrolotriazinforbindelser som kinasehæmmere | |
IS7717A (is) | Pýrídasínónafleiður sem PDF4-hemlar | |
IS7534A (is) | Pýrazóló-pýrimídín anilín efnasambönd, gagnleg sem kínasatálmar | |
IL172132A0 (en) | Thienopyridone derivatives as kinase inhibitors | |
AU2003271566A8 (en) | Pyrrolopyrazines as kinase inhibitors | |
DK1448523T3 (da) | Heterocycliske forbindelser samt metoder til anvendelse deraf | |
NO20034389D0 (no) | Fremgangsmåte for utledning av data | |
NO20082223L (no) | Fremgangsmåte for inhibering av FLT3-kinase | |
EP1778693A4 (en) | AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL | |
IS8089A (is) | Efnasambönd | |
PL378116A1 (pl) | Heterocykliczne inhibitory kinazy | |
HK1096398A1 (en) | Method for the manufacture of thip thip | |
NO20055097D0 (no) | Krystallinske N-formyl-hydroksylaminforbindelser | |
DE10390373D2 (de) | Phosphorchelatverbindungen | |
GB0314980D0 (en) | Methods for identifying compounds | |
NO20031736D0 (no) | Forbindelser | |
HU0200269D0 (en) | Method for determination the stability of compounds | |
ITRE20030033U1 (it) | Astuccio per piccoli oggetti | |
NO20033173D0 (no) | Forbindelser |